Long-term Intervention with Pravastatin in Ischaemic Disease. The trial has been completed and patients are still being followed up to examine the long-term safety and cost-effectiveness of pravastatin.
LIPID (Long-term Intervention with Pravastatin in Ischaemic Disease) was a large multicentre trial begun in 1990, of the effects of pravastatin in 9014 patients with coronary heart disease and average cholesterol levels.The randomised phase of the trial finished in 1997 and showed that pravastatin significantly reduced the risk of death, myocardial infarction and other cardiovascular events. Of the 7882 patients who completed the main trial, 7680 consented to be followed up, and 85% of these patients opted to take pravastatin (90% were taking pravastatin or another cholesterol-lowering drug). Results of the first two years of follow-up showed that the pravastatin therapy during the earlier years of the main trial continued to benefit patients.
Eligibility & Criteria
LIPID project manager: Helen Pater